Cytek Biosciences, Inc.
CTKB
$4.21
-$0.16-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -557.08% | -682.77% | 46.49% | -84.83% | 75.23% |
| Total Depreciation and Amortization | 11.02% | 8.94% | 20.48% | 17.24% | 13.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 994.97% | -66.47% | -42.36% | -7.82% | -190.12% |
| Change in Net Operating Assets | 36.82% | -209.33% | -109.68% | 64.00% | -43.27% |
| Cash from Operations | -138.61% | -129.48% | -98.26% | -103.16% | -79.01% |
| Capital Expenditure | -11.97% | 35.01% | -49.76% | -49.74% | 40.40% |
| Sale of Property, Plant, and Equipment | 2.09% | -95.24% | -69.74% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -99.58% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.34% | 232.10% | -595.47% | 297.96% | -302.13% |
| Cash from Investing | 97.10% | 219.68% | -911.72% | 264.27% | -318.24% |
| Total Debt Issued | -49.16% | 41,720.00% | 46,266.67% | -50.50% | -- |
| Total Debt Repaid | -2,015.11% | -3.57% | -2.16% | -992.09% | 0.71% |
| Issuance of Common Stock | -36.41% | -6.80% | -37.69% | -92.29% | -32.11% |
| Repurchase of Common Stock | 96.71% | 98.83% | -64.71% | -7,167.57% | 79.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 66.32% | 116.06% | -52.07% | -815.75% | 89.22% |
| Foreign Exchange rate Adjustments | -6.98% | 189.71% | -140.72% | -172.45% | 284.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.18% | 214.06% | -325.92% | -328.06% | -1,688.55% |